Knud Schewe

Datos Biográficos

ID8933655
NOMBREKnud Schewe
NOMBRESKnud
APELLIDOSchewe
FIRMASCHEWE K
AFILIACIONESInfektionsmedizinisches Centrum Hamburg, Hamburg, Germany
VERIFICADONo
TOTAL DE OBRAS3
TOTAL DE CITAS0
TOTAL COMO AUTOR3
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2014
AÑO MÁS RECIENTE DE PUBLICACIÓN2023
ÍNDICE H0

  • Socio-demographic and psycho-social determinants of HIV late presentation in Germany – results from the FindHIV study

    Paul Lauscher, Nikola Hanhoff et al.ARTICLEAIDS Care2023

    Delayed HIV diagnosis at advanced stages of disease remains common (33%–64%). This analysis of the multi-center FindHIV study including newly diagnosed HIV-infected adults in Germany, focused on the potential role of socio-demographic and psychological factors on late diagnosis (formerly “late presentation”, AIDS diagnosis or CD4 cells <350/μL). These data were collected from patient profiles, physician-patient interviews and questionnaires. Part…

  • Understanding and avoiding late presentation for HIV diagnosis – study protocol of a trial using mixed methods (FindHIV)

    Open AccessFrederik Valbert, Eva Wolf et al.ARTICLEAIDS Care2021

    Many patients infected with HIV are diagnosed at an advanced stage of illness. These late presenters are individuals with a CD4 cell count of less than 350 cells/μL and/or an AIDS defining disease at initial HIV diagnosis. Purpose of FindHIV is to develop and distribute a questionnaire/scoring system aimed at a reduction in late presentation. FindHIV uses a mixed methods approach. In a first step, primary data of patients were collected. Inclusio…

  • Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada

    Kevin Robertson, Carmen Bayón et al.ARTICLEAIDS Care2014

    CRANIum, a cross-sectional epidemiology study in Western Europe and Canada, was conducted to describe and compare the prevalence of a positive screen for neurocognitive impairment (NCI), depressive symptoms, and anxiety in an HIV-positive population either receiving combination antiretroviral therapy (cART) or who were naive to antiretroviral therapy (ART). HIV-positive patients ≥18 years of age attending a routine medical follow-up visit and abl…